Results 31 to 40 of about 643 (132)

Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies?

, 2022
Clinical Pharmacology &Therapeutics, Volume 112, Issue 3, Page 453-455, September 2022.
Anees M. Dauki, Chia‐Hsiang Hsueh, Ganesh Cherala, Ahmed A. Othman   +3 more
wiley   +1 more source

Human and nonclinical disposition of [¹⁴C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

, 2022
Bictegravir (BIC) is a potent small-molecule integrase strand-transfer inhibitor (INSTI) and a component of Biktarvy®, a single-tablet combination regimen that is currently approved for the treatment of human immunodeficiency virus type 1 (HIV-1 ...
Bernard Murray (3187821), Kelly Wang (1834006), Haolun Jin (1834141), Jianhong Wang (225432), Yurong Lai (1286232), Samantha Wijaya (14293633), John Ling (15748), Jia Hao (444898), Heather Zhang (2471923), Bill J. Smith (9454239), Raju Subramanian (1855276)   +10 more
core   +1 more source

Late Onset Immune Reconstitution Inflammatory Syndrome presentingas Infectious Meningitis [PDF]

, 2022
A 35-year-old African American male with no significant past medical history presented with generalized weakness, fatigue, cough, progressive 50-pound weight loss in the last 2 months, frontal headache, neck stiffness, and blurry vision.
Griffin, Carl J., Nelson, Jacob A., Kawji, Yasmeen, Hosse, Alexander G.   +3 more
core   +1 more source

A Stable Switch From Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) to Dolutegravir/Lamivudine (DTG/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort. [PDF]

Cureus
 This article aims to examine the safety and efficacy of switching from bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) to dolutegravir and lamivudine (DTG/3TC) in the absence of prior resistance records. Switch to Dovato in patients suppressed on Biktarvy (SOUND) is an open-label, single-arm, pilot study of adult people with HIV who were ...
Slim J, Bellafiore P, Touza M, Fallon JP, Borsi RA.   +4 more
europepmc   +3 more sources

Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus‐Associated Disorders

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Kaposi sarcoma herpes virus (KSHV) is associated with multiple clinical manifestations, including primary effusion lymphoma, an aggressive CD38+ B cell lymphoma with a plasmablastic phenotype. Case This case describes an antiretroviral therapy‐adherent person with HIV who presented with concurrent KSHV‐related disorders of Kaposi ...
Kandice Roberts, Paula Valiño Ramos, Saurabh Jindal, Vikas Prasad, Yi Shan Lee, Mariam Khanfar, Obi L. Griffith, Malachi Griffith, Jeanne Jiang, Ethel Cesarman, Daniel Rauch, Paul Simonson, Thomas Odeny, Lee Ratner   +13 more
wiley   +1 more source

Development and Validation of a Simple and Robust Bioanalytical Method for Simultaneous Quantification of Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Human Plasma Using LC–MS/MS and Its Application in a Pharmacokinetic Study

SEPARATION SCIENCE PLUS, Volume 9, Issue 4, April 2026.
ABSTRACT A simple, sensitive, and selective LC–MS/MS method has been developed and validated, in accordance with ICH M10 guidelines, for the simultaneous quantification of Bictegravir (BTV), Emtricitabine (ECB), and Tenofovir alafenamide (TAM) in human plasma.
Boosi Ravi Kumar, Muvvala Venkatanarayana, Shiva Kumar Koppula, Valluru Rajani Kumar   +3 more
wiley   +1 more source

The ‘Informed Matter’ of Gay and Bisexual Men's (Potential) Use of HIV Antiretrovirals to Prevent COVID‐19

Sociology of Health &Illness, Volume 47, Issue 7, September 2025.
ABSTRACT In 2020, there were reports that HIV antiretrovirals, specifically the combination tenofovir disoproxil fumarate and emtricitabine (TDF/FTC), had therapeutic potential for COVID‐19. In the context of scant empirical evidence at the time to confirm such an effect, we sought to understand the ways that gay and bisexual men (GBM) made sense of ...
Daniel Storer, Dean Murphy, Niamh Stephenson, Garrett Prestage, Mohamed A. Hammoud   +4 more
wiley   +1 more source

Consideration of ethnic differences in approvals for anti‐HIV medicines in Japan: Evaluation based on pharmacokinetic studies and post‐marketing data

British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2474-2479, August 2025.
More than 30 anti‐HIV drugs have been approved in Japan using data from dossiers submitted to the United States or European regulatory authorities since 1998. These drugs were approved with the same dosage and administration regimes as in the United States and Europe, using data from pivotal studies that rarely included any Japanese patients, whereas ...
Rumiko Shimazawa, Masayuki Ikeda
wiley   +1 more source

Nephrotic Syndrome: Beyond Common Causes

Nephrology, Volume 30, Issue 4, April 2025.
ABSTRACT We report the case of a 38‐year‐old Caucasian man with well‐controlled HIV on antiretroviral therapy who developed nephrotic syndrome. The patient presented with a maculopapular rash, lymphadenopathy, oral lesions, nasal congestion and bilateral pitting oedema. Laboratory tests revealed hypoalbuminemia, nephrotic range proteinuria and abnormal
Humam Hazim, Ryan Horn, Ashwati Krishnan Varikara, Joanna Mesure, Bobby Chacko   +4 more
wiley   +1 more source

Correspondence on ‘Pulmonary endocarditis due to Neisseria gonorrhoeae in a patient living with HIV’ by Cabras et al

, 2016
International audienceA 49-year-old heterosexual man was admitted after three episodes of loss of consciousness. He had received a diagnosis of HIV infection in 2002 and was virologically suppressed on Biktarvy (CD4 count 499/mm3, nadir 302/mm3). Medical
Cabras, Ornella, Turmel, Jean-Marie, Cuzin, Lise, Rami, Andrea   +3 more
core   +1 more source